Recently, Edan Instruments released its 2025 earnings forecast, projecting a 75% to 105% year-over-year increase in net profit attributable to shareholders of the listed company. This significant growth is primarily driven by the company’s continued expansion in the global medical device market, optimization of its product portfolio, and enhanced cost-control capabilities. In recent years, Edan has focused on core business segments such as high-end patient monitoring, ultrasound diagnostics, and in-vitro diagnostics, consistently increasing R&D investment to drive technological innovation and product upgrades. The company has also actively expanded its overseas presence, achieving strong sales growth—particularly in emerging markets—which has further boosted overall profitability. Additionally, rising global demand for primary healthcare and home-based health monitoring has created favorable conditions for Edan, whose portable and intelligent medical devices have effectively captured these market opportunities. The company stated that it will continue to deepen its globalization strategy, strengthen supply chain management, and accelerate digital transformation to support long-term, sustainable growth. This earnings forecast not only reflects Edan Instruments’ robust operational resilience but also underscores its competitive strength and brand influence in the global medical device industry.
近日，理邦仪器（Edan Instruments）发布2025年业绩预告，预计全年归属于上市公司股东的净利润将同比增长75%至105%。这一显著增长主要得益于公司在全球医疗设备市场的持续拓展、产品结构优化以及成本控制能力的提升。近年来，理邦仪器聚焦于高端监护、超声诊断和体外诊断等核心业务领域，不断加大研发投入，推动技术创新与产品升级。同时，公司积极布局海外市场，尤其在新兴市场国家取得良好销售增长，进一步增强了整体盈利能力。此外，随着全球对基层医疗和家庭健康监测需求的上升，理邦凭借其便携式、智能化的医疗设备产品线，成功抓住了市场机遇。公司表示，未来将继续深化全球化战略，强化供应链管理，并加快数字化转型，以支撑长期可持续增长。此次业绩预增不仅体现了理邦仪器强劲的经营韧性，也彰显了其在国内外医疗设备行业中的竞争力与品牌影响力。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/17700.html